2. Academic Validation
  3. An update on inhibitors of human 14 kDa Type II s-PLA2 in development

An update on inhibitors of human 14 kDa Type II s-PLA2 in development

  • Curr Pharm Des. 2001 Feb;7(3):181-98. doi: 10.2174/1381612013398275.
D M Springer 1
Affiliations

Affiliation

  • 1 Anti-infective Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, P.O. Box 5100, Wallingford, CT 06492, USA.
PMID: 11311112 DOI: 10.2174/1381612013398275
Abstract

Recent progress in the development of inhibitors of human Type II s-PLA2 as potential anti-inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY-315920 (S-5920) as a potential treatment for sepsis and Other Diseases that have an inflammatory component. The Lilly developmental effort leading to LY-315920 is extensively reviewed, as well as the current status of Other small molecular weight inhibitors of Type II s-PLA2 that have been reported to be in late-stage development

Figures
Products